Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF
Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF Summary
Accession # Q92956.3
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
HVEM (herpesvirus entry mediator), also known as TNFRSF14 and CD270, is a type I membrane protein in the TNF receptor superfamily, and it can both promote and inhibit T cell activity (1). Mature human HVEM consists of a 164 amino acid (aa) extracellular domain (ECD) with three cysteine-rich domains (CRD), a 21 aa transmembrane segment, and a 60 aa cytoplasmic tail with a TRAF interaction domain (2, 3). Within the ECD, human HVEM shares 55% aa sequence identity with mouse and rat HVEM. Alternative splicing generates an additional isoform with a substitution of the N-terminal 10 amino acids including the signal peptide. HVEM is highly expressed on naïve CD4+ T cells, CD8+ T memory cells, regulatory T cells, dendritic cells, monocytes, and neutrophils (4-8). Its expression declines during effector T cell activation but is up-regulated during Treg activation (4, 5). HVEM functions as a receptor for BTLA, CD160, LIGHT/TNFSF14, and Lymphotoxin-alpha (4, 9‑12). Ligation of HVEM by LIGHT triggers T cell, monocyte, and neutrophil activation (8, 10) and contributes to Th1 inflammation and cardiac allograft rejection (13, 14). In contrast, HVEM binding to CD160 or BTLA suppresses T cell and dendritic cell activation (4, 7, 9, 10) and dampens intestinal inflammation (15). HVEM enhances the development of CD8+ T cell memory and Treg function (5, 6). It is additionally expressed on intestinal epithelial cells, where its binding by intraepithelial lymphocyte (IEL) expressed CD160 promotes epitheilal integrity and host defense (16). The herpesvirus envelope glycoprotein gD, which binds HVEM to initiate membrane fusion, can antagonize both BTLA and LIGHT binding (2, 9, 11).
- del Rio, M.L. et al. (2010) J. Leukoc. Biol. 87:223.
- Montgomery, R.I. et al. (1996) Cell 87:427.
- Hsu, H. et al. (1997) J. Biol. Chem. 272:13471.
- Sedy, J. R. et al. (2005) Nat. Immunol. 6:90.
- Tao, R. et al. (2008) J. Immunol. 180:6649.
- Steinberg, M.W. et al. (2013) PLoS One 8:e77992.
- de Trez, C. et al. (2008) J. Immunol. 180:238.
- Heo, S.K. et al. (2006) J. Leukoc. Biol. 79:330.
- Gonzalez, L.C. et al. (2005) Proc. Natl. Acad Sci. USA 102:1116.
- Cai, G. et al. (2008) Nat. Immunol. 9:176.
- Mauri, D.N. et al. (1998) Immunity 8:21.
- Harrop, J.A. et al. (1998) J. Biol. Chem. 273:27548.
- Wang, J. et al. (2005) J. Immunol. 174:8173.
- Ye, Q. et al. (2002) J. Exp. Med. 195:795.
- Steinberg, M.W. et al. (2008) J. Exp. Med. 205:1463.
- Shui, J.W. et al. (2012) Nature 488:222.
Citations for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Authors: Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan W, Malek S, Ennishi D, Brentjens R, Gascoyne R, Cogne M, Tarte K, Wendel H
Sample Types: Whole Cells
CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
Authors: El-Far, Mohamed, Pellerin, Charles, Pilote, Louise, Fortin, Jean-Fra, Lessard, Ivan A D, Peretz, Yoav, Wardrop, Elizabet, Salois, Patrick, Bethell, Richard, Cordingley, Michael, Kukolj, George
J Transl Med, 2014-09-02;12(0):217.
Sample Types: Whole Cells
Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.
Authors: Morishige T, Yoshioka Y, Inakura H, Tanabe A, Yao X, Tsunoda S, Tsutsumi Y, Mukai Y, Okada N, Nakagawa S
Applications: Surface Plasmon Resonance
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image